Clinical-stage biopharmaceutical company Seelos Therapeutics (NASDAQ: SEEL) has closed a sale of 4,475,000 shares of common stock with certain institutional investors. According to the update, the offering resulted in approximately $6.7 million in total gross proceeds, with each of the shares sold at a price of $1.50. The company has also agreed to issue the investors, in a concurrent private placement, unregistered warrants to purchase up to 2,237,500 shares of common stock. The warrants have an exercise price of $1.78 per common stock share and will be exercisable six months and expire four years from the date of issuance. Seelos Therapeutics intends to use offering proceeds for general corporate purposes and to advance the development of its product candidates. ROTH Capital Partners acted as the sole placement agent for the offering.
To view the full press release, visit http://nnw.fm/sp0WL
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (“CNS”) disorders and other rare disorders. The company’s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit www.SeelosTherapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]